NPPA Warns Drugmakers Against Arbitrary Pricing, Calls for MRP Uniformity

Published On 2025-07-26 17:22 GMT   |   Update On 2025-07-26 17:22 GMT
Advertisement

New Delhi: In a move to ensure uniform pricing and check arbitrary price differences across pharmaceutical brands, the National Pharmaceutical Pricing Authority (NPPA) has directed all drug manufacturers to align the Maximum Retail Prices of non-scheduled formulations launched under different brand names.

This directive is based on Paragraph 20 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). Paragraph 20 of the Drugs (Prices Control) Order (DPCO), 2013 governs the monitoring of Maximum Retail Prices (MRP) of non-scheduled formulations, including new drugs and medical devices that are not included in Schedule-I of the DPCO.

The NPPA has observed that certain manufacturers are marketing the same formulation under multiple brands with unjustifiable MRP differences. To address this, the authority has mandated that such variations must not exceed 10 percent.

The official directive stated: “All manufacturers are hereby directed to align the prices of non-scheduled formulation launched under different brands, as per the provisions of para 20 of the DPCO, 2013, so that the difference in MRP is not more than ten percent.”

Advertisement

This directive holds critical importance for maintaining pricing consistency in the pharmaceutical market and promoting affordability for patients who often encounter significant cost discrepancies for the same drug sold under different brand names.

Further, the NPPA has cautioned manufacturers against any violations of the order. Non-compliance will invite penal action under both the DPCO, 2013 and the Essential Commodities Act, 1955. The directive specifically noted: “Any violation of the provision specified in para 4 above shall attract penal action under the provisions of the DPCO, 2013 and Section 7 of the Essential Commodities Act, 1955.”

All stakeholders have been asked to ensure strict compliance with the pricing norms laid out under DPCO, 2013 to avoid regulatory action and support patient welfare.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News